Short answer
Teva Pharmaceutical Industries Ltd (TEVA) filed its Q3 2026 10-Q quarterly report on Nov 3, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $4.4B (down 1.9% year over year) with net income of $233M.
Q3 2026 key financials · XBRL
- Revenue
- $4.4B
- −1.9% YoY · +6.1% QoQ
- Net income
- $233M
- −46.2% YoY · +140.5% QoQ
- Operating margin
- 16.2%
- Gross margin
- 55.5%
- EPS (diluted)
- $0.20
- −45.9% YoY · +140.8% QoQ
Source: XBRL data from the Teva Pharmaceutical Industries Ltd (TEVA) Q3 2026 10-Q on SEC EDGAR. USD.
Teva Pharmaceutical Industries Ltd Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $4,395M, down 2% YoY from $4,395M, driven by lower generic sales, especially lenalidomide
- Gross margin 55.5% vs 51.4%; operating margin 16.2% vs 19.7%, with operating income $714M vs $882M
- Best segment: Europe revenue $1,319M, up 7%, profit $420M, up 39%; worst: U.S. revenue $1,870M, down 11%
- Cash $4,085M vs $3,556M at December 31; operating cash flow $241M vs $369M, free cash flow $495M vs $515M
- Headwinds: tariffs, geopolitical supply-chain disruptions, generic competition; AUSTEDO prices reduced for eligible Medicare patients January 1, 2027
Risk Factors
- No material changes to risk factors disclosed in the December 31, 2025 Form 10-K
- Carried-forward regulatory risk, pharmaceutical compliance obligations remain material
- Carried-forward operational risk, competitive pressures may affect performance
- Carried-forward financial risk, debt and liquidity exposures remain relevant
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Teva Pharmaceutical Industries Ltd quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.